Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease and
β-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning,
has provided stable reductions in disease burden and opioid dependence.
